Type 2 Diabetes: New Ozempic Pill Now Available in the U.S.

Novo Nordisk has announced that its reformulated oral semaglutide pill, previously branded as Rybelsus, is now available as the "Ozempic pill" for adults with type 2 diabetes in the United States, starting May 4, 2026.

The smaller, reformulated pill is available in dosages of 1.5 mg, 4 mg, and 9 mg,different from Rybelsus's 3 mg, 7 mg, and 14 mg tablets. Novo Nordisk states it offers the same efficacy and safety profile as the original formulation but in a smaller size. Patients should take it the same way, with equivalents such as 1.5 mg replacing the prior 3 mg dose.

The Ozempic pill is available nationwide through more than 70,000 pharmacies, select telehealth providers, and mail-order services. It is intended to improve blood glucose control alongside diet and exercise and to reduce major cardiovascular events,including heart attack, stroke, or death,in adults with type 2 diabetes at increased risk. Learn more about GLP-1 drugs like Ozempic revolutionizing treatment.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist that mimics a hormone to increase insulin secretion, slow gastric emptying, and reduce appetite. It has FDA approval for treating type 2 diabetes and for long-term weight management. See how Ozempic and similar GLP-1s are changing obesity care.

The injectable form is known as Ozempic, while the oral form,Rybelsus,was first approved by the FDA in 2019.

Key Changes from Rybelsus

Rybelsus was the first FDA-approved oral GLP-1 receptor agonist for type 2 diabetes. The rebrand to Ozempic pill, announced in February 2026, aims to leverage the more widely recognized Ozempic name.

“While the oral form of semaglutide has been available for years as Rybelsus, the Ozempic branding is more widely recognized, which may lead to increased patient requests.”

The pill is manufactured end-to-end in the U.S. and offered for the first time through Novo Nordisk’s direct-to-patient service.

Oral vs. Injectable Semaglutide

The choice between oral and injectable forms depends on individual preferences and should be discussed with a healthcare professional. GLP-1s like semaglutide show broader benefits.

Research indicates injectable semaglutide achieves greater HbA1c reductions than the oral form in people with type 2 diabetes (PMC). Adverse events occur more frequently with oral semaglutide (PMC).

“The primary advantages of oral GLP-1 medications are that they are easier to take, transport, and store. They are also typically less expensive to manufacture, which could lead to lower costs for patients. The disadvantages are that they are slightly less effective than injections and require daily instead of weekly administration.”

Pricing and Access

For insured patients, the Ozempic pill may cost as little as $25 for up to a 3-month supply. Self-pay options through Novo Nordisk’s pharmacy and select telehealth providers range from $149 to $299 per month, based on a 30-pill bottle and dose strength.

This is potentially more affordable than self-pay injectable Ozempic, which costs $349 per month for doses up to 1 mg and $499 for 2 mg.

“Pricing and insurance coverage are significant factors in medication adherence. High out-of-pocket expenses make patients less likely to seek or maintain treatment. Consequently, if costs remain high, individuals in lower socioeconomic areas with limited health coverage will face significant barriers to accessing these medications.”

“Accessibility is critical, especially as these medications are in high demand and have faced shortages,” Ali added. “Lack of access often leads patients to switch to less effective alternatives or discontinue treatment entirely.”

Broader Context and Cardiovascular Benefits

The Ozempic pill reflects a shift toward oral GLP-1 therapies, following the FDA approval of Eli Lilly’s oral GLP-1, Foundayo, for weight loss in April 2026.

“Real-world cardiovascular benefits are linked to weight loss, improved blood pressure, and reduced inflammation. Some studies have shown a reduction in major adverse cardiovascular events by 18-20%. Patients with diabetes, obesity, and existing atherosclerotic cardiovascular disease stand to benefit the most,” Ali noted.

For full prescribing information, see Rybelsus label and dosing guidance here. FDA.gov provides general guidance on GLP-1 therapies.